Background

Mouse studies show that tumor-derived prostaglandins and platelets promote melanoma progression and immune evasion.

Objective

Determine whether aspirin confers longer survival in patients with melanoma.

Methods

A retrospective cohort study of 1522 patients at Indiana University Health who had melanoma diagnosed between 2000 and 2014 and were followed up through September 2016.

Results

Aspirin use was associated with longer overall survival in univariate analysis and after controlling for age, sex, stage, and treatment modalities (hazard ratio [HR], 0.58; 95% confidence interval [CI], 0.45-0.75). Aspirin use was not associated with survival in patients with in situ and stage I melanoma but was associated with better survival in stages II (HR, 0.45; 95% CI, 0.24-0.82) and III (HR, 0.57; 95% CI; 0.34-0.96). No statistical significance was observed in stage IV patients (HR, 0.55; 95% CI, 0.27-1.13). In turn, melanoma in patients using aspirin before diagnosis was less likely to be diagnosed in stages III or IV.

Limitations

Observational study.

Conclusions

Aspirin could provide a survival advantage in melanoma. Clinical trials investigating the therapeutic potential of aspirin are warranted.

中文翻译：

---

黑色素瘤患者的诊断后阿司匹林使用和总生存

背景

小鼠研究表明，肿瘤衍生的前列腺素和血小板可促进黑色素瘤的进展和免疫逃逸。

客观的

确定阿司匹林是否可延长黑色素瘤患者的生存期。

方法

回顾性队列研究对2000年至2014年间诊断为黑色素瘤的1522例患者进行了回顾性研究，并随访至2016年9月。

结果

在单变量分析中以及在控制了年龄，性别，阶段和治疗方式后，使用阿司匹林与更长的总生存期相关（危险比[HR]为0.58； 95％置信区间[CI]为0.45-0.75）。阿司匹林的使用与原位和I期黑色素瘤患者的生存率无关，但与II期（HR，0.45； 95％CI，0.24-0.82）和III期（HR，0.57； 95％CI； 0.34）的更好生存相关。 -0.96）。在IV期患者中未观察到统计学意义（HR，0.55； 95％CI，0.27-1.13）。反过来，在诊断前使用阿司匹林的患者的黑色素瘤在III或IV期的诊断可能性较小。

局限性

观察研究。

结论

阿司匹林可以在黑色素瘤中提供生存优势。有必要对阿司匹林的治疗潜力进行临床试验。